Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity Withdrawn Phase 2 Trials for 2-(1-Hexyloxyethyl)-2-devinyl pyropheophorbide-a (DB15243)

IndicationStatusPhase
DBCOND0028768 (Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity)Withdrawn2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02119728Photodynamic Therapy With HPPH in Treating Patients With Squamous Cell Carcinoma of the Oral CavityTreatment